Accelerated approval and breakthrough therapy designation: Oncology drug development on speed?

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4305-4308

  Yao, James C ^a   Meric Bernstam, Funda ^a   Lee, J Jack ^a   Eckhardt, S Gail ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCELERATED APPROVAL AND BREAKTHROUGH THERAPY DESIGNATION; ADVANCED CANCER; ARTICLE; BIOTECHNOLOGY; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; HEALTH CARE QUALITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROFESSIONAL STANDARD; STUDY DESIGN; SYSTEMATIC ERROR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883006303     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1428     Document Type: Article

References (8)

1. CenterWatch. [cited 2013 June 14]. Available from: http://www.center- watch.com/drug-information/ fda-approvals/.
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-5.
3. Wilson WH, Schenkein DP, Jernigan CL, Woodcock J, Schilsky RL. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res 2013;19:2804-9.
4. Horning SJ, Haber DA, Selig WKD, Ivy SP, Roberts SA, Allen JD, et al. Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013 May 29. [Epub ahead of print].
5. Sharma MR, Stadler WM, Ratain MJ. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 2011;103:1093-100.
6. LoRusso PM, Anderson AB, Boerner SA, Averbuch SD. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? Clin Cancer Res 2010;16:5956-62.
7. Halperin DM, Lee JJ, Yao JC. Predictive value of phase II clinical trials in pancreatic cancer: rethinking the road to progress. J Clin Oncol 31, 2013 (suppl; abstr 4036).
8. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 2011;103:636-44.